Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)-Reference-Cited by-同舟云学术

Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

Published:2014-09 Issue: Volume:25 Page:v1
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lenz H.,Niedzwiecki D.,Innocenti F.,Blanke C.,Mahony M.R.,O'Neil B.H.,Shaw J.E.,Polite B.,Hochster H.,Atkins J.,Goldberg R.,Mayer R.,Schilsky R.L.,Bertagnolli M.,Venook A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/suppl_4/mdu438.13/9692403/mdu438.13.pdf

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review;Medicina;2024-04-24

2. Modulation of intestinal permeability of 5-fluorouracil via phospholipid interaction based lipophilic complex designing and pharmacokinetic assessment;Journal of Dispersion Science and Technology;2024-03-05

3. Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer;Cancers;2023-09-01

4. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer;JAMA;2023-04-18

5. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2023-01